Virtual at your computer Floorplan
This meeting took place in 2020
Here are the related meetings in 2024:
Myeloid Cell Diversity: From Fundamental Biology to Disease States (A3)
Myeloid Targeting Strategies for Cancer Treatment (C7)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Myeloid Cells and Innate Immunity in Solid Tumors (EK4)
Organizer(s) Judith A. Varner, Lisa M. Coussens and Dmitry I. Gabrilovich
September 21—23, 2020
Virtual at your computer • , CO USA
Abstract Deadline: Sep 3, 2020
Scholarship Deadline: Aug 24, 2020
Discounted Registration Deadline:
Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation
Sponsored by AbbVie Inc., AstraZeneca, and Gilead Sciences, Inc.
Sponsored by AbbVie Inc., AstraZeneca, and Gilead Sciences, Inc.
Summary of Meeting:
The field of cancer immunology is moving at a rapid pace, with discoveries based on T cell biology and T cell targeted therapeutics eliciting real clinical successes and excitement about the future of cancer care. However, as only twenty percent of patients respond to T cell targeted therapeutics, further work must be done to harness the power of immunology in cancer care. Recent research has shown that myeloid cells create major roadblocks to cancer eradication by promoting immune suppression, angiogenesis and resistance to immune therapy. Advances in the science of these diverse cell types, roles and mechanisms governing myeloid cells in cancer, along with the recent developments of myeloid cell targeted therapeutics, has generated significant interest in the academic and pharmaceutical communities. Conferences that gather experts to focus discussion exclusively on roles of myeloid cells and innate immunity in cancer will help to move our understanding of cancer immune suppression and the field of cancer immune therapy forward. The objectives of this proposed conference are to present the latest developments in our understanding of the origins and contributions of various myeloid cell subsets to tumor growth and metastasis. Additionally, this conference will challenge paradigms about macrophage and granulocyte origins in tumors, about links between metabolism and function, and about mechanisms by which myeloid cells control immunity. The conference will also feature the latest clinical studies of myeloid cell targeted therapeutics in cancer which will stimulate new ideas, collaborations and advance development of new cancer immune therapeutics.
View Scholarships/Awards
The field of cancer immunology is moving at a rapid pace, with discoveries based on T cell biology and T cell targeted therapeutics eliciting real clinical successes and excitement about the future of cancer care. However, as only twenty percent of patients respond to T cell targeted therapeutics, further work must be done to harness the power of immunology in cancer care. Recent research has shown that myeloid cells create major roadblocks to cancer eradication by promoting immune suppression, angiogenesis and resistance to immune therapy. Advances in the science of these diverse cell types, roles and mechanisms governing myeloid cells in cancer, along with the recent developments of myeloid cell targeted therapeutics, has generated significant interest in the academic and pharmaceutical communities. Conferences that gather experts to focus discussion exclusively on roles of myeloid cells and innate immunity in cancer will help to move our understanding of cancer immune suppression and the field of cancer immune therapy forward. The objectives of this proposed conference are to present the latest developments in our understanding of the origins and contributions of various myeloid cell subsets to tumor growth and metastasis. Additionally, this conference will challenge paradigms about macrophage and granulocyte origins in tumors, about links between metabolism and function, and about mechanisms by which myeloid cells control immunity. The conference will also feature the latest clinical studies of myeloid cell targeted therapeutics in cancer which will stimulate new ideas, collaborations and advance development of new cancer immune therapeutics.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Monday, September 21 with . Conference events conclude on Wednesday, September 23 with a closing plenary session from 15:00 to , followed by . We recommend return travel on Thursday, September 24 in order to fully experience the meeting.
MONDAY, SEPTEMBER 21
TUESDAY, SEPTEMBER 22
WEDNESDAY, SEPTEMBER 23
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Monday, September 21 with . Conference events conclude on Wednesday, September 23 with a closing plenary session from 15:00 to , followed by . We recommend return travel on Thursday, September 24 in order to fully experience the meeting.
MONDAY, SEPTEMBER 21
08:00—08:30
Opening Remarks and Keynote Address (8am Denver/Mountain Time Start)
*
Judith A. Varner,
University of California, San Diego, USA
Session Chair
Session Chair
Robert H. Vonderheide,
University of Pennsylvania, USA
CD40 as a Gateway Pathway in the Tumor Microenvironment
CD40 as a Gateway Pathway in the Tumor Microenvironment
08:30—11:00
Ontogeny of Myeloid Cells in Cancer (8:30am Denver/Mountain Time Start)
Miriam Merad,
Mount Sinai School of Medicine, USA
Identification of a Dendritic Cells Immunoregulatory Program that Dampens Tumor Specific Immunity
Identification of a Dendritic Cells Immunoregulatory Program that Dampens Tumor Specific Immunity
*
Judith A. Varner,
University of California, San Diego, USA
Mechanisms Governing Accumulation of Macrophages in Cancer
Mechanisms Governing Accumulation of Macrophages in Cancer
Coffee Break
David G. DeNardo,
Washington University Medical School, USA
Origins of Macrophages in Pancreatic Cancer
Origins of Macrophages in Pancreatic Cancer
*
Dmitry I. Gabrilovich,
AstraZeneca, USA
Monocyte-Like Precursors of Granulocytes in Cancer
Monocyte-Like Precursors of Granulocytes in Cancer
Chang Su,
Duke University, USA
Short Talk: Dissecting the Role of MerTK Signaling in Promoting Alternatively Activated Macrophages Polarization
Short Talk: Dissecting the Role of MerTK Signaling in Promoting Alternatively Activated Macrophages Polarization
Danielle N. Huggins,
University of Minnesota, USA
Short Talk: Single Cell Sequencing Identifies Novel Metastasis-Associated Macrophage Subsets in the Lung
Short Talk: Single Cell Sequencing Identifies Novel Metastasis-Associated Macrophage Subsets in the Lung
13:30—15:00
Poster Session (1:30pm Denver/Mountain Time Start)
15:00—18:00
Epigenetics, Metabolism and Metastasis of Myeloid Cells in Cancer (3pm Denver/Mountain Time Start)
Gwendalyn J. Randolph,
Washington University, USA
Serous Cavity Macrophages and Ovarian Cancer in the Peritoneum-Studies in Mice
Serous Cavity Macrophages and Ovarian Cancer in the Peritoneum-Studies in Mice
*
Catherine Hedrick,
La Jolla Institute for Immunology, USA
Myeloid Cells in Modulating Cancer Metastasis
Myeloid Cells in Modulating Cancer Metastasis
*
Weiping Zou,
University of Michigan, USA
Impact of Autophagy on Tumor-Associated Macrophages and Cancer Metastasis
Impact of Autophagy on Tumor-Associated Macrophages and Cancer Metastasis
Coffee Break
Diana Hargreaves,
The Salk Institute for Biological Studies, USA
Epigenetic Control of Myeloid Cells in Cancer
Epigenetic Control of Myeloid Cells in Cancer
Florent Ginhoux,
Singapore Immunology Network, Singapore
Macrophage and Dendritic Cell Biology: From Development to Functions
Macrophage and Dendritic Cell Biology: From Development to Functions
Ferdinando Pucci,
Oregon Health & Science University, USA
Short Talk: Tumor-Immune Communication via Extracellular Vesicles: A Lymph Node Macrophage Link
Short Talk: Tumor-Immune Communication via Extracellular Vesicles: A Lymph Node Macrophage Link
Rachel Cederberg,
BC Cancer Research Centre, Canada
Short Talk: Eosinophils Inhibit Pulmonary Metastasis and Directly Kill Tumor Cells
Short Talk: Eosinophils Inhibit Pulmonary Metastasis and Directly Kill Tumor Cells
08:00—11:00
Immune Suppression and Metastasis Mediated by Myeloid Cells (8am Denver/Mountain Time Start)
*
Jeffrey W. Pollard,
Queen's Medical Research Institute, UK
Re-tuning the Tumor Microenvironment to Promote Immunotherapy
Re-tuning the Tumor Microenvironment to Promote Immunotherapy
Jo A. Van Ginderachter,
VIB-Vrije Universiteit Brussel, Belgium
Transcriptional Profiling of Glioblastoma-Associated Myeloid Cells across Species and Disease Stage Reveals Macrophage Competition and Functional Specialization
Transcriptional Profiling of Glioblastoma-Associated Myeloid Cells across Species and Disease Stage Reveals Macrophage Competition and Functional Specialization
*
Vincenzo Bronte,
University of Verona, Italy
DAB2-Expressing TAMs Promote Cancer Cell Invasion
DAB2-Expressing TAMs Promote Cancer Cell Invasion
Coffee Break
Antonio Sica,
University of Eastern Piedmont, Italy
Metabolic Regulation of Myeloid Derived Suppressor Cells in Cancer
Metabolic Regulation of Myeloid Derived Suppressor Cells in Cancer
Michael C. Schmid,
University of Liverpool, UK
Myeloid Cells in Pancreatic Cancer Metastasis
Myeloid Cells in Pancreatic Cancer Metastasis
Pierre Close,
Fondation Leon Fredericq, Belgium
Short Talk: Wobble tRNA Modification and Translation Reprogramming in the Tumour Microenvironment during Breast Cancer Development
Short Talk: Wobble tRNA Modification and Translation Reprogramming in the Tumour Microenvironment during Breast Cancer Development
Hafsa Munir,
University of Cambridge, UK
Short Talk: Amyloid β Secreted by the Tumor Microenvironment Drives Neutrophil Extracellular Traps Production to Support Tumor Progression
Short Talk: Amyloid β Secreted by the Tumor Microenvironment Drives Neutrophil Extracellular Traps Production to Support Tumor Progression
12:30—13:30
Career Roundtable (12:30pm Denver/Mountain Time Start)
Simon T. Barry,
AstraZeneca, UK
Claudia Jakubzick,
Dartmouth College, USA
Rosandra Natasha Kaplan,
NCI, National Institutes of Health, USA
13:30—15:00
Poster Session (1:30pm Denver/Mountain Time Start)
15:00—18:00
Promotion of Tumor Progression by Myeloid Cells (3pm Denver/Mountain Time Start)
*
Mikala Egeblad,
Cold Spring Harbor Laboratory, USA
Activating a Collaborative Innate-Adaptive Immune Response to Control Metastasis
Activating a Collaborative Innate-Adaptive Immune Response to Control Metastasis
Minna Roh-Johnson,
University of Utah, USA
Horizontal Transfer of Macrophage Mitochondria in Cancer
Horizontal Transfer of Macrophage Mitochondria in Cancer
Claudia Jakubzick,
Dartmouth College, USA
Rediscovering the Role of B Cells in Cancer Immune Surveillance
Rediscovering the Role of B Cells in Cancer Immune Surveillance
Coffee Break
Shruti Naik,
New York University Langone Health, USA
Eavesdropping on the Conversation between Immune and Epithelial Stem Cells during Tissue Repair
Eavesdropping on the Conversation between Immune and Epithelial Stem Cells during Tissue Repair
*
Rosandra Natasha Kaplan,
NCI, National Institutes of Health, USA
Myeloid Cells as Regulators of Immune Suppression in the Pre-Metastatic Niche and Myeloid Based Approaches to Rebalance the Dysregulated Niche
Myeloid Cells as Regulators of Immune Suppression in the Pre-Metastatic Niche and Myeloid Based Approaches to Rebalance the Dysregulated Niche
Mingjian Fei,
Genentech, USA
Short Talk: Blocking Dying Tumor Cell Clearance Enhances Antitumor Immune Response
Short Talk: Blocking Dying Tumor Cell Clearance Enhances Antitumor Immune Response
Ziyan Zoe Xu,
The Salk Institute, USA
Short Talk: Lipid Metabolism Controls Macrophage Functional Reprogramming in Tumor Microenvironment
Short Talk: Lipid Metabolism Controls Macrophage Functional Reprogramming in Tumor Microenvironment
08:00—11:00
Targeting Myeloid Cells in Cancer Therapy I (8am Denver/Mountain Time Start)
*
Lisa M. Coussens,
Oregon Health & Science University, USA
Therapeutic Targeting of Macrophages: Lessons Learned from Mouse Models and Their Translation to the Clinic
Therapeutic Targeting of Macrophages: Lessons Learned from Mouse Models and Their Translation to the Clinic
Limin Shang,
Light Chain Bioscience, Switzerland
CD47 Targeting in Cancer Therapy
CD47 Targeting in Cancer Therapy
*
Simon T. Barry,
AstraZeneca, UK
Therapeutic Targeting of Macrophages and Neutrophils
Therapeutic Targeting of Macrophages and Neutrophils
Coffee Break
Nagy A. Habib,
Imperial College London and MiNA Therapeutics, UK
MTL - CEBPA - Next Generation Immunotherapy Targeting Myeloid Cell Differentiation
MTL - CEBPA - Next Generation Immunotherapy Targeting Myeloid Cell Differentiation
Sven Brandau,
University Hospital Essen, Germany
Short Talk: Unravelling the Identity and Function of MDSC in Human Cancer Patients
Short Talk: Unravelling the Identity and Function of MDSC in Human Cancer Patients
Yolanda Calle,
University of Roehampton, UK
Short Talk: Therapeutic Drugs Promote Differentiation of AML Blasts to a Mixed M1/M2 and Migratory Phenotype Resistant to Treatment Facilitated by the Bone Marrow Microenvironment.
Short Talk: Therapeutic Drugs Promote Differentiation of AML Blasts to a Mixed M1/M2 and Migratory Phenotype Resistant to Treatment Facilitated by the Bone Marrow Microenvironment.
Natalie Horvat,
European Molecular Biological Laboratories, Germany
Short Talk: Polarization of TAMs by Iron Nanoparticles as an Adjuvant Lung Cancer Therapy
Short Talk: Polarization of TAMs by Iron Nanoparticles as an Adjuvant Lung Cancer Therapy
13:30—15:00
Poster Session (1:30pm Denver/Mountain Time Start)
15:00—17:45
Targeting Myeloid Cells in Cancer Therapy II (3pm Denver/Mountain Time Start)
Brenda C. O'Connell,
Infinity Pharmaceuticals, Inc, USA
Targeting PI3K-gamma with IPI-549, a Tumor Macrophage-Reprogramming Small Molecule, in Patients with Advanced Solid Tumors
Targeting PI3K-gamma with IPI-549, a Tumor Macrophage-Reprogramming Small Molecule, in Patients with Advanced Solid Tumors
*
Jennifer Guerriero,
Brigham and Women's Hospital, USA
Differentiating Macrophages are Regulated by PARP Inhibitors and can be Harnessed to Overcome PARP-Inhibitor Resistance in BRCA-Associated Triple-Negative Breast Cancer
Differentiating Macrophages are Regulated by PARP Inhibitors and can be Harnessed to Overcome PARP-Inhibitor Resistance in BRCA-Associated Triple-Negative Breast Cancer
*
David A. Cheresh,
University of California, San Diego, USA
Arming Tumor-Associated Macrophages to Reverse Epithelial Cancer Progression
Arming Tumor-Associated Macrophages to Reverse Epithelial Cancer Progression
Coffee Break
Caroline Bonnans,
Immune-Onc Therapeutics, USA
Short Talk: Antagonistic Antibodies Targeting LAIR1 Promote Inflammatory Phenotypes in Myeloid Cells and Activate Lymphocytes
Short Talk: Antagonistic Antibodies Targeting LAIR1 Promote Inflammatory Phenotypes in Myeloid Cells and Activate Lymphocytes
Shadi Swaidani,
Cleveland Clinic Foundation, USA
Short Talk: Elevated Systemic Myeloid-Derived Suppressor Cells and Interleukin 8 Correlate with Increased Incidence of Venous Thromboembolism in Cancer Patients Receiving Immune-Checkpoint Inhibitors
Short Talk: Elevated Systemic Myeloid-Derived Suppressor Cells and Interleukin 8 Correlate with Increased Incidence of Venous Thromboembolism in Cancer Patients Receiving Immune-Checkpoint Inhibitors
Mehdi Chaib,
University of Tennessee Health Science Center, USA
Short Talk: PKC Delta Activation Restricts Innate Immune Suppression and Promotes antigen Presentation in Triple Negative Breast Cancer
Short Talk: PKC Delta Activation Restricts Innate Immune Suppression and Promotes antigen Presentation in Triple Negative Breast Cancer
Jihong Bae,
Korea Advanced Institute of Science and Technology, South Korea
Short Talk: Extracellular Vesicles Derived from a Commensal Bacteria Enhance Anticancer Immunity by Modulating Tumor Infiltrating Immune Cells
Short Talk: Extracellular Vesicles Derived from a Commensal Bacteria Enhance Anticancer Immunity by Modulating Tumor Infiltrating Immune Cells
17:45—18:00
Closing Remarks (Organizers) (5:45pm Denver/Mountain Time Start)
*Session Chair †Invited, not yet responded.
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
We gratefully acknowledge the generous grant for this conference provided by:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: John Monson,
Director of Corporate Relations, Email: johnm@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Josh May, Director, Technology and Digital Media, Email: joshuam@keystonesymposia.org, Phone:+1 970-262-1179 |